Clinical characteristics of 28 patients tested using anti-HLA-B61 antibody
| Case . | Age, years . | Sex . | Severity . | Before/after IST . | Years after IST . | IST . | Response to IST . | % of B4002−granulocytes . | Phenotype of B4002−granulocytes . | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6pLOH (%) . | B4002−A+ (%) . | |||||||||
| 1 | 68 | M | Nonsevere | After | 17 | CsA | CR | 24 | 0 | 6pLOH |
| 2 | 59 | M | Severe | After | 6.2 | ATG/CsA | CR | 99 | 0 | 6pLOH |
| 3 | 41 | M | Severe | After | 17 | ATG/CsA | CR | 0 | 60 | B4002−A+ |
| 4 | 72 | M | Very severe | After | 2.3 | ATG/CsA | PR | 0 | 2 | B4002−A+ |
| 5 | 30 | M | Severe | After | 1.9 | ATG/CsA | PR | 0 | 8 | B4002−A+ |
| 6 | 87 | F | Severe | After | 23 | ATG/CsA | CR | 0 | 10 | B4002−A+ |
| 7 | 15 | M | Severe | After | 3.7 | ATG/CsA | PR | 0 | 53 | B4002−A+ |
| 8 | 57 | F | Severe | After | 2.5 | ATG/CsA | PR | 0 | 1 | B4002−A+ |
| 9 | 54 | F | Nonsevere | After | 14 | CsA | PR | 0 | 99 | B4002−A+ |
| 10 | 56 | F | Nonsevere | After | 0.4 | CsA | NR | 0 | 70 | B4002−A+ |
| 11 | 57 | M | Severe | After | 1.9 | CsA | PR | 0 | 3 | B4002−A+ |
| 12 | 74 | F | Nonsevere | After | 25 | CsA | CR | 13 | 15 | B4002−A+ and 6pLOH |
| 13 | 69 | F | Nonsevere | After | 6.4 | CsA | PR | 97 | 3 | B4002−A+ and 6pLOH |
| 14 | 49 | F | Severe | After | 0.6 | ATG/CsA | PR | 43 | 1 | B4002−A+ and 6pLOH |
| 15 | 79 | F | Nonsevere | After | 1.5 | CsA | CR | 17 | 17 | B4002−A+ and 6pLOH |
| 16 | 21 | F | Very severe | Before | NA | ATG/CsA | CR | 8 | 75 | B4002−A+ and 6pLOH |
| 17 | 38 | M | Nonsevere | After | 2.2 | CsA | PR | 36 | 58 | B4002−A+ and 6pLOH |
| 18 | 81 | F | Severe | Before | NA | No IST | NA | 67 | 33 | B4002−A+ and 6pLOH |
| 19 | 28 | M | Very severe | After | 14 | ATG/CsA | CR | 39 | 40 | B4002−A+ and 6pLOH |
| 20 | 32 | M | Very severe | Before | NA | ATG/CsA | PR | 21 | 52 | B4002−A+ and 6pLOH |
| 21 | 81 | M | Severe | Before | NA | CsA | NR | 19 | 25 | B4002−A+ and 6pLOH |
| 22 | 66 | F | Nonsevere | After | 8.1 | ATG/CsA | CR | 0 | 0 | None |
| 23 | 68 | M | Nonsevere | After | 1.7 | CsA | CR | 0 | 0 | None |
| 24 | 25 | M | Nonsevere | After | 0.6 | ATG/CsA | NR | 0 | 0 | None |
| 25 | 39 | M | Severe | After | 2.8 | ATG/CsA | CR | 0 | 0 | None |
| 26 | 71 | F | Nonsevere | After | 1.4 | ATG/CsA | PR | 0 | 0 | None |
| 27 | 24 | F | Nonsevere | After | 2.2 | CsA | NR | 0 | 0 | None |
| 28 | 56 | M | Nonsevere | Before | NA | No IST | NA | 0 | 0 | None |
| Case . | Age, years . | Sex . | Severity . | Before/after IST . | Years after IST . | IST . | Response to IST . | % of B4002−granulocytes . | Phenotype of B4002−granulocytes . | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6pLOH (%) . | B4002−A+ (%) . | |||||||||
| 1 | 68 | M | Nonsevere | After | 17 | CsA | CR | 24 | 0 | 6pLOH |
| 2 | 59 | M | Severe | After | 6.2 | ATG/CsA | CR | 99 | 0 | 6pLOH |
| 3 | 41 | M | Severe | After | 17 | ATG/CsA | CR | 0 | 60 | B4002−A+ |
| 4 | 72 | M | Very severe | After | 2.3 | ATG/CsA | PR | 0 | 2 | B4002−A+ |
| 5 | 30 | M | Severe | After | 1.9 | ATG/CsA | PR | 0 | 8 | B4002−A+ |
| 6 | 87 | F | Severe | After | 23 | ATG/CsA | CR | 0 | 10 | B4002−A+ |
| 7 | 15 | M | Severe | After | 3.7 | ATG/CsA | PR | 0 | 53 | B4002−A+ |
| 8 | 57 | F | Severe | After | 2.5 | ATG/CsA | PR | 0 | 1 | B4002−A+ |
| 9 | 54 | F | Nonsevere | After | 14 | CsA | PR | 0 | 99 | B4002−A+ |
| 10 | 56 | F | Nonsevere | After | 0.4 | CsA | NR | 0 | 70 | B4002−A+ |
| 11 | 57 | M | Severe | After | 1.9 | CsA | PR | 0 | 3 | B4002−A+ |
| 12 | 74 | F | Nonsevere | After | 25 | CsA | CR | 13 | 15 | B4002−A+ and 6pLOH |
| 13 | 69 | F | Nonsevere | After | 6.4 | CsA | PR | 97 | 3 | B4002−A+ and 6pLOH |
| 14 | 49 | F | Severe | After | 0.6 | ATG/CsA | PR | 43 | 1 | B4002−A+ and 6pLOH |
| 15 | 79 | F | Nonsevere | After | 1.5 | CsA | CR | 17 | 17 | B4002−A+ and 6pLOH |
| 16 | 21 | F | Very severe | Before | NA | ATG/CsA | CR | 8 | 75 | B4002−A+ and 6pLOH |
| 17 | 38 | M | Nonsevere | After | 2.2 | CsA | PR | 36 | 58 | B4002−A+ and 6pLOH |
| 18 | 81 | F | Severe | Before | NA | No IST | NA | 67 | 33 | B4002−A+ and 6pLOH |
| 19 | 28 | M | Very severe | After | 14 | ATG/CsA | CR | 39 | 40 | B4002−A+ and 6pLOH |
| 20 | 32 | M | Very severe | Before | NA | ATG/CsA | PR | 21 | 52 | B4002−A+ and 6pLOH |
| 21 | 81 | M | Severe | Before | NA | CsA | NR | 19 | 25 | B4002−A+ and 6pLOH |
| 22 | 66 | F | Nonsevere | After | 8.1 | ATG/CsA | CR | 0 | 0 | None |
| 23 | 68 | M | Nonsevere | After | 1.7 | CsA | CR | 0 | 0 | None |
| 24 | 25 | M | Nonsevere | After | 0.6 | ATG/CsA | NR | 0 | 0 | None |
| 25 | 39 | M | Severe | After | 2.8 | ATG/CsA | CR | 0 | 0 | None |
| 26 | 71 | F | Nonsevere | After | 1.4 | ATG/CsA | PR | 0 | 0 | None |
| 27 | 24 | F | Nonsevere | After | 2.2 | CsA | NR | 0 | 0 | None |
| 28 | 56 | M | Nonsevere | Before | NA | No IST | NA | 0 | 0 | None |
B4002− granulocytes are granulocytes that lost HLA-B4002 expression as a result of 6pLOH or HLA-B*40:02 mutations. B4002−A+ granulocytes are B4002− granulocytes that retain the HLA-A allele on the same haplotype.
CR, complete response; F, female; M, male; NA, not applicable; NR, no response; PR, partial response.